ARCHIVES

Research teams link response to Iressa to mutations in EGF receptor.

This article is from The Cancer Letter archive.

Vol. 30 No. 18 | April 30, 2004

Download PDF Visit The Full Archive

Related Articles

Device Shortens Time To Make T Cells For Immunotherapy

March 27, 2009

NCI advisors approve recompetition of $62 million phase II contracts program.

November 19, 2004

ACS Board Accepts Hammer’s ffer, Will Support Construction Survey

February 17, 1984

Cuts Claimed to Displace “Millions” of Patients Yet None Seem to Complain. Why Not?

April 25, 2013

Program Announcement In Preventative Oncology

May 21, 1982

In Brief: Patent For Semisynthetic Taxol Issued To FL Scientist; Simone To Chair Pediatric Group

June 7, 1991